Prospects for the control of neglected tropical diseases by mass drug administration

References

• WHO Expert Committee. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ. Tech. Rep. Ser.912, 1–57 (2002).
   Google Scholar
• Hotez P, Ottesen E, Fenwick A et al. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv. Exp. Med. Biol.582, 23–33 (2006).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Molyneux DH, Fenwick A, Molyneux D. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med.3, E102 (2006).
   PubMed Web of Science ®Google Scholar
• Finkelstein JL, Schleinitz MD, Carabin H, McGarvey ST. Decision-model estimation of the age-specific disability weight for schistosomiasis japonica: a systematic review of the literature. PLoS Negl. Trop. Dis.5, E158 (2008).
   Google Scholar
• Engels D, Savioli L. Reconsidering the underestimated burden caused by neglected tropical diseases. Trends Parasitol.22, 363–366 (2006).
   PubMed Web of Science ®Google Scholar
• Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull. World Health Organ.75, 491–503 (1997).
   PubMed Web of Science ®Google Scholar
• Savioli L, Engels D, Endo H. Extending the benefits of de-worming for development. Lancet365, 1520–1521 (2005).
   PubMed Web of Science ®Google Scholar
• Hotez P, Raff S, Fenwick A, Richards F Jr, Molyneux DH. Recent progress in integrated neglected tropical disease control. Trends Parasitol.23, 511–514 (2007).
   PubMed Web of Science ®Google Scholar
• Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem. Biol.11, 433–439 (2007).
   PubMed Web of Science ®Google Scholar
• Fox LM. Ivermectin: uses and impact 20 years on. Curr. Opin. Infect. Dis.19, 588–593 (2006).
   PubMed Web of Science ®Google Scholar
• Thylefors B, Alleman M. Towards the elimination of onchocerciasis. Ann. Trop. Med. Parasitol.100, 733–746 (2006).
   PubMed Web of Science ®Google Scholar
• Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. Clin. Infect. Dis.44, 53–60 (2007).
   PubMed Web of Science ®Google Scholar
• Sommer A. Systemic antibiotics for communitywide trachoma control. Arch. Ophthalmol.123, 687–688 (2005).
   PubMedGoogle Scholar
• Solomon AW, Holland MJ, Alexander ND et al. Mass treatment with single-dose azithromycin for trachoma. N. Engl. J. Med.351, 1962–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Lansdown R, Ledward A, Hall A et al. Schistosomiasis, helminth infection and health education in Tanzania: achieving behaviour change in primary schools. Health Educ. Res.17, 425–433 (2002).
   PubMed Web of Science ®Google Scholar
• Gunawerda S, Ismail M, Bradley M Kuranaweera N. Factors influencing drug compliance in the mass drug administration programme against filariasis in the western province of Sri Lanka. Trans. R. Soc. Trop. Med. Hyg.101, 445–453 (2007).
   PubMed Web of Science ®Google Scholar
• Stettler A. Changes in prevention of infection: a historic retrospect. Ther. Umsch.48, 205–209 (1991).
   PubMed Web of Science ®Google Scholar
• Ruiz-Tiben E, Hopkins DR. Dracunculiasis (Guinea worm disease) eradication. Adv. Parasitol.61, 275–309 (2006).
   PubMed Web of Science ®Google Scholar
• Voelker R. Persistence pays off in Guinea worm fight. JAMA298, 1856–1857 (2007).
   PubMed Web of Science ®Google Scholar
• Iriemenam NC, Oyibo WA, Fagbenro-Beyioku AF. Dracunculiasis – the saddle is virtually ended. Parasitol. Res.102, 343–347 (2008).
   PubMed Web of Science ®Google Scholar
• Hotez P. Measuring neglect. PLoS Negl. Trop. Dis.1, 118–119 (2007).
   PubMed Web of Science ®Google Scholar
• Mathers CD, Ezzatti M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl. Trop. Dis.1, E114 (2007).
   PubMed Web of Science ®Google Scholar
• Brooker S, Kabatereine NB, Fleming F, Devlin N. Cost and cost–effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up. Health Policy Plan.23, 24–35 (2008).
   PubMed Web of Science ®Google Scholar
• Fox LM, Furnness BW, Haser JK et al. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. Am. J. Trop. Med. Hyg.73, 115–121 (2005).
   PubMedGoogle Scholar
• Beach MJ, Streit TG, Addiss DG, Prospere, R, Roberts JM, Lammie PJ. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am. J. Trop. Med. Hyg.60, 479–486 (1999).
   PubMed Web of Science ®Google Scholar
• Olds GR, King C, Hewlett J et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J. Infect. Dis.179, 996–1003 (1999).
   PubMed Web of Science ®Google Scholar
• Na-Bangchang K, Kierinun S, Pawa KK, Hanpitakpong W, Na-Bangchang C, Lazdins J. Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. Trans. R. Soc. Trop. Med. Hyg.100, 335–345 (2006).
   PubMed Web of Science ®Google Scholar
• Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA298, 1911–1924 (2007).
   PubMed Web of Science ®Google Scholar
• Olsen A. Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Trans. R. Soc. Trop. Med. Hyg.101, 747–758 (2007).
   PubMed Web of Science ®Google Scholar
• Mohammed KA, Haji HJ, Gabrielli AF et al. Triple co-administration of ivermectin, albendazole and praziquantel in Zanzibar: a safety study. PLoS Negl. Trop. Dis.2, E171 (2008).
   PubMed Web of Science ®Google Scholar
• Emerson PM, Ngondi J, Biru E et al. Integrating an NTD with one of “the big three”: combined malaria and trachoma survey in Amhara region of Ethiopia. PLoS Negl. Trop. Dis.2, E197 (2008).
   PubMed Web of Science ®Google Scholar
• Holveck JC, Eherenberg JP, Ault SK et al. Prevention, control, and elimination of neglected diseases in the Americas: pathways to integrated, inter-programmatic, inter-sectoral action for health and development. BMC Public Health7, 6 (2007).
   PubMedGoogle Scholar
• Bethony J, Brooker S, Albonico M et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet367, 1521–1532 (2006).
   PubMed Web of Science ®Google Scholar
• Galvani AP. Age-dependent epidemiological patterns and strain diversity in helminth parasites. J. Parasitol.91, 24–30 (2005).
   PubMed Web of Science ®Google Scholar
• Chan L, Bundy DA, Kan SP. Aggregation and predisposition to Ascaris lumbricoides and Trichuris trichiura at the familial level. Trans. R. Soc. Trop. Med. Hyg.88, 46–48 (1994).
   PubMed Web of Science ®Google Scholar
• Forrester JE, Scott ME, Bundy DA, Golden MH. Predisposition of individuals and families in Mexico to heavy infection with Ascaris lumbricoides and Trichuris trichiura. Trans. R. Soc. Trop. Med. Hyg.84, 272–276 (1990).
   PubMed Web of Science ®Google Scholar
• Bethony J, Chen J, Lin S et al. Emerging patterns of hookworm infection: influence of aging on the intensity of Necator infection in Hainan province, People’s Republic of China. Clin. Infect. Dis.35, 1336–1344 (2002).
   PubMed Web of Science ®Google Scholar
• Horton J. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr. Opin. Infect. Dis.15, 599–608 (2002).
   PubMed Web of Science ®Google Scholar
• Stephenson LS. Optimising the benefits of anthelmintic treatment in children. Paediatr. Drugs3, 495–508 (2001).
   PubMedGoogle Scholar
• Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA299, 1937–1948 (2008).
   PubMed Web of Science ®Google Scholar
• Quinnell RJ, Slater AF, Tighe P Walsh EA, Keymer AE, Pritchard DI. Reinfection with hookworm after chemotherapy in Papua New Guinea. Parasitology106, 379–385 (1993).
   PubMed Web of Science ®Google Scholar
• Haswell-Elkins MR, Elkins DB, Anderson RM. Evidence for predisposition in humans to infection with Ascaris, hookworm, Enterobius and Trichuris in a South Indian fishing community. Parasitology95, 323–337 (1987).
   PubMed Web of Science ®Google Scholar
• Chan L, Kan SP, Bundy DA. The effect of repeated chemotherapy on the prevalence and intensity of Ascaris lumbricoides and Trichuris trichiura infection. Southeast Asian J. Trop. Med. Public Health23, 228–234 (1992).
   PubMedGoogle Scholar
• Sirivichayakul C, Pojjaroen-Anant C, Wisetsing P, Praevanit R, Chantavanich P, Limkittikul K. The effectiveness of 3, 5 or 7 days of albendazole for the treatment of Trichuris trichiura infection. Ann. Trop. Med. Parasitol.97, 847–853 (2003).
   PubMed Web of Science ®Google Scholar
• Ismail MM, Jayakody RL. Efficacy of albendazole and its combinations with ivermectin or diethylcarbamazine (DEC) in the treatment of Trichuris trichiura infections in Sri Lanka. Ann. Trop. Med. Parasitol.93, 501–504 (1999).
   PubMed Web of Science ®Google Scholar
• Kabatereine NB, Brooker S, Koulounari A et al. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull. World Health Organ.85, 91–99 (2007).
   PubMed Web of Science ®Google Scholar
• Bundy D, Wong MS, Lewis LL, Horton J. Control of geohelminths by delivery of targeted chemotherapy through schools. Trans. R. Soc. Trop. Med. Hyg.84, 115–120 (1990).
   PubMed Web of Science ®Google Scholar
• Poggensee G, Krantz I, Nordin P et al. A six-year follow-up of schoolchildren for urinary and intestinal schistosomiasis and soil-transmitted helminthiasis in Northern Tanzania. Acta Trop.93, 131–140 (2005).
   PubMed Web of Science ®Google Scholar
• Dickson R, Awasthi S, Williamson P, Demellweek C, Garner P. Effects of treatment for intestinal helminth infection on growth and cognitive performance in children: systematic review of randomized trials. BMJ320, 1697–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Dickson R, Awasthi S, Demellweek C, Willaimson P. Anthelmintic drugs for treating worms in children: effects on growth and cognitive performance. Cochrane Database Syst. Rev.2, CD000371 (2000).
   Google Scholar
• Hall H. Micronutrient supplements for children after deworming. Lancet Infect. Dis.7, 297–302 (2007).
   PubMed Web of Science ®Google Scholar
• Ramahrishnan U, Aburto N, McCabe G, Martorell R. Multimicronutrient interventions but not vitamin A or iron interventions alone improve child growth: results of 3 meta-analyses. J. Nutr.134, 2592–2602 (2004).
   PubMed Web of Science ®Google Scholar
• Longfils P, Heang UK, Soeng H, Sinuon M. Weekly iron and folic acid supplementation as a tool to reduce anemia among primary school children in Cambodia. Nutr. Rev.63, S139–S145 (2005).
   Google Scholar
• Stoltzfus RJ, Chwaya HM, Montresor A, Albonico M, Savioli L, Tielsch JM. Malaria, hookworms and recent fever are related to anemia and iron status indicators in 0- to 5-y old Zanzibari children and these relationships change with age. J. Nutr.130, 1724–1733 (2000).
   PubMed Web of Science ®Google Scholar
• Urbani C, Albbonic M. Anthelminthic drug safety and drug administration in the control of soil-transmitted helminthiasis in community campaigns. Acta Trop.86, 215–221 (2003).
   PubMed Web of Science ®Google Scholar
• Montresor A, Awashti S, Crompton DW. Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. Acta Trop.86, 223–232 (2003).
   PubMed Web of Science ®Google Scholar
• Larocque R, Csapia M, Gotuzzo E, Gyorkos TW. Relationship between intensity of soil-transmitted helminth infections and anemia during pregnancy. Am. J. Trop. Med. Hyg.73, 783–789 (2005).
   PubMed Web of Science ®Google Scholar
• Larocque R, Cssapia M, Gotuzzo E et al. A double-blind randomized controlled trial of antenatal mebendazole to reduce low birthweight in a hookworm-endemic area of Peru. Trop. Med. Int. Health11, 1485–1495 (2006).
   PubMed Web of Science ®Google Scholar
• Gyrokos TW, Larocque R, Casapia M, Gotuzzo E. Lack of risk of adverse birth outcomes after deworming in pregnant women. Pediatr. Infect. Dis. J.25, 791–794 (2006).
   PubMed Web of Science ®Google Scholar
• WHO. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions – A Manual for Health Professionals and Programme Manager. WHO, Geneva, Switzerland (2006).
   Google Scholar
• Merino G, Alvarez AI, Prieto JG, Kim RB. The anthelminthic agent albendazole does not interact with P-glycoprotein. Drug Metab. Dispos.30, 365–369 (2002).
   PubMed Web of Science ®Google Scholar
• Albonico M, Engels D, Savioli L. Monitoring drug efficacy and early detection of drug resistance in human soil-transmitted nematodes: a pressing public health agenda for helminth control. Int. J. Parasitol.34, 1205–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Wolstenholme AJ, Fairweather I, Prichard R, von Samson-Himmelsiema G, Sangster NC. Drug resistance in veterinary helminths. Trends Parasitol.20, 469–476 (2004).
   PubMed Web of Science ®Google Scholar
• Lubega GW, Prichard RK. Specific interaction of benzimidazole anthelmintics with tubulin: high-affinity binding and benzimidazole resistance in Haemonchus contortus. Mol. Biochem. Parasitol.38, 221–232 (1990).
   PubMed Web of Science ®Google Scholar
• Kwa MSG, Veenstra JG, Roos MH. Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in β tubulin isotype 1. Mol. Biochem. Parasitol.63, 299–303 (1994).
   PubMed Web of Science ®Google Scholar
• Schwab AE, Boakye DA, Kyelem D, Prichard RK. Detection of benzimidazole resistance-associated mutations in the filarial nematode Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am. J. Trop. Med. Hyg.73, 234–238 (2005).
   PubMed Web of Science ®Google Scholar
• Albinoco M, Wright V, Bcikle Q. Molecular analysis of the β-tubulin gene of human hookworms as a basis for possible benzimidazole resistance on Pemba Island. Mol. Biochem. Parasitol.134, 281–284 (2004).
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali Q, Elwali NE, Abdelhameed AA et al. Susceptibility to periportal (Symmers) fibrosis in human Schistosoma mansoni infections: evidence that intensity and duration of infection, gender, and inherited factors are critical in disease progression. J. Infect. Dis.180, 1298–1306 (1999).
   PubMed Web of Science ®Google Scholar
• Mayer DA, Fried B. The role of helminth infections in carcinogenesis. Adv. Parasitol.65, 239–296 (2007).
   PubMed Web of Science ®Google Scholar
• Smith JH, Christie JD. The pathobiology of Schistosoma haematobium infection in humans. Hum. Pathol.17, 333–345 (1986).
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev. Anti Infect. Ther.4, 199–210 (2006).
   PubMedGoogle Scholar
• Botros, Sayed H, Amer N, El-Ghannam M, Bennnett JL, Day TA. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int. J. Parasitol.35, 787–791 (2005).
   PubMed Web of Science ®Google Scholar
• Olds GR. Administration of praziquantel to pregnant and lactating women. Acta Trop.86, 185–195 (2003).
   PubMed Web of Science ®Google Scholar
• Adam I, Elwasila El T, Homeida M. Is praziquantel therapy safe during pregnancy? Trans. R. Soc. Trop. Med. Hyg.98, 540–543 (2004).
   PubMed Web of Science ®Google Scholar
• Idowu ET, Mafe MA, Appelt B et al. Height as a substitute for weight for estimating praziquantel dosage. World Health Popul.9, 19–26 (2007).
   PubMedGoogle Scholar
• Montresor A, Odermatt P, Muth S et al. The WHO dose pole for the administration of praziquantel is also accurate in non-African populations. Trans. R. Soc. Trop. Med. Hyg.99, 78–81 (2005).
   PubMed Web of Science ®Google Scholar
• Sturrock RF, Klump RK, Ouma JH et al. Observations on the effects of different chemotherapy strategies on the transmission of Schistosoma mansoni in Machakos District, Kenya, measured by long-term snail sampling and cercariometry. Parasitology109, 443–453 (1994).
   PubMed Web of Science ®Google Scholar
• King CH, Muchiri E, Ouma JH, Koech D. Chemotherapy-based control of Schistosomiasis haematobia. IV. Impact of repeated annual chemotherapy on prevalence and intensity of Schistosoma haematobium infection in an endemic area of Kenya. Am. J. Trop. Med. Hyg.45, 498–508 (1991).
   PubMed Web of Science ®Google Scholar
• N’Goran EK, Utzinger J, N’Guessan AN et al. Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d’Ivoire. Trop. Med. Int. Health6, 817–825 (2001).
   PubMed Web of Science ®Google Scholar
• Hatz CF, Vennervald BJ, Nkulila T. et al. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in Southeastern Tanzania. Am. J. Trop. Med. Hyg.59, 775–781 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Koukounari A, Kabatereine N et al. Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda. BMC Med.5, 27 (2007).
   PubMed Web of Science ®Google Scholar
• Liang S, Yang C, Zhing B, Qiu D. Re-emerging schistosomiasis in hilly and mountainous areas of Sichuan, China. Bull. World Health Organ.84, 139–144 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou YB, Zhao GM, Jiang QW. Effects of the praziquantel-based control of Schistosomiasis japonica in China. Ann. Trop. Med. Parasitol.101, 695–703 (2007).
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ohmae H, Panginan R, Redulla A, Matsuda H. Modeling the dynamics and control of Schistosoma japonicum transmission on Bohol island, The Philippines. Parasitol. Int.55, 23–29 (2006).
   PubMed Web of Science ®Google Scholar
• Williams GM, Sleigh AC, Li Y et al. Mathematical modelling of Schistosomiasis japonica: comparison of control strategies in the People’s Republic of China. Acta Trop.82, 253–262 (2002).
   PubMed Web of Science ®Google Scholar
• Li YS, Raso G, Zhao ZY, He YK, Ellis MK, Mcmanus DP. Large water management projects and schistosomiasis control, Dongting Lake region, China. Emerg. Infect. Dis.13, 973–979 (2007).
   PubMed Web of Science ®Google Scholar
• Stainmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis.6, 411–425 (2006).
   PubMed Web of Science ®Google Scholar
• van der Werf MJ, de Vlas SJ, Brooker S et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop.86, 125–139 (2003).
   PubMed Web of Science ®Google Scholar
• Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop.82, 139–146 (2002).
   PubMed Web of Science ®Google Scholar
• Keiser J, Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin. Pharmacother.5, 1711–1726 (2004).
   PubMed Web of Science ®Google Scholar
• Figueredo-Silva J, Norões J, Cedenho A, Dreyer G. The histopathology of bancroftian filariasis revisited: the role of the adult worm in the lymphatic-vessel disease. Ann. Trop. Med. Parasitol.96, 531–551 (2002).
   PubMed Web of Science ®Google Scholar
• Noroes J, Addiss D, Cedenho A, Figeuredo-Silva J, Lima G, Dreyer G. Pathogenesis of filarial hydrocele: risk associated with intrascrotal nodules caused by death of adult Wuchereria bancrofti. Trans. R. Soc. Trop. Med. Hyg.97, 561–566 (2003).
   PubMed Web of Science ®Google Scholar
• Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Trop. Med. Int. Health6, 582–606 (2001).
   PubMed Web of Science ®Google Scholar
• Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol. Today15, 382–386 (1999).
   PubMedGoogle Scholar
• Horton J, Witt C, Ottesen EA et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology121, S147–S160 (2000).
   PubMed Web of Science ®Google Scholar
• Moulia-Pelat JP, Glaziou P, Weil GJ, Nguyen LN, Gaxotte P, Nicolas L. Combination ivermectin plus diethylcarbamazine, a new effective tool for control of lymphatic filariasis. Trop. Med. Parasitol.46, 9–12 (1995).
   PubMedGoogle Scholar
• Gardon J, Gardon-Wendeli N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussonesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet350, 18–22 (1997).
   PubMed Web of Science ®Google Scholar
• Palumbo E. Filariasis: diagnosis, treatment and prevention. Acta Biomed.79, 106–109 (2008).
   PubMedGoogle Scholar
• Ismail MM, Weil GJ, Jayasinghe KS et al. Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazine. Trans. R. Soc. Trop. Med. Hyg.90, 684–688 (1996).
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Guinea A, Weil GJ, Ottessen EA. Clearance of circulating filarial antigen as a measure of the macrofilaricidal activity of diethylcarbamazine in Wuchereria bancrofti infection. J. Infect. Dis.172, 521–526 (1995).
   PubMed Web of Science ®Google Scholar
• Eberhard ML, Hightower AW, Addiss DG, Lammie PJ. Clearance of Wuchereria bancrofti antigen after treatment with diethylcarbamazine or ivermectin. Am. J. Trop. Med. Hyg.57, 483–486 (1997).
   PubMed Web of Science ®Google Scholar
• Nicolas L, Plichart C, Nguyen LN, Moulia-Pelat JP. Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. J. Infect. Dis.175, 489–492 (1997).
   PubMed Web of Science ®Google Scholar
• Dunyo SK, Nkrumah FK, Simonsen PE. Single-dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Trans. R. Soc. Trop. Med. Hyg.94, 437–443 (2000).
   PubMed Web of Science ®Google Scholar
• Stolk WA, van Oortmarssen GJ, Pani SP et al. Effects of ivermectin and diethylcarbamazine on microfilariae and overall microfilaria production in bancroftian filariasis. Am. J. Trop. Med. Hyg.73, 881–887 (2005).
   PubMed Web of Science ®Google Scholar
• Gyapong JO, Kumaraswami V, Biswas G, Ottessen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin. Pharmacother.6, 179–200 (2005).
   PubMed Web of Science ®Google Scholar
• Esterre P, Plitchart C, Sechan Y, Nguyen NL. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop. Med. Int. Health6, 190–195 (2001).
   PubMed Web of Science ®Google Scholar
• Meyrowitsch DW, Simonsen PE, Magesa SM. A 26-year follow-up of bancroftian filariasis in two communities in North-eastern Tanzania. Ann. Trop. Med. Parasitol.98, 155–169 (2004).
   PubMed Web of Science ®Google Scholar
• Schlemper BR Jr, Steindel M, Grisard EC et al. Elimination of bancroftian filariasis (Wuchereria bancrofti) in Santa Catarina state, Brazil. Trop. Med. Int. Health5, 848–854 (2000).
   PubMed Web of Science ®Google Scholar
• de Kraker ME, Stolk WA, van Oortmarssen GJ, Habbema JD. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. Trop. Med. Int. Health11, 718–728 (2006).
   PubMed Web of Science ®Google Scholar
• Michael E, Malecela-Lazaro MN, Maegga BT, Fischer P, Kazura JW. Mathematical models and lymphatic filariasis control: monitoring and evaluating interventions. Trends Parasitol.22, 529–535 (2006).
   PubMed Web of Science ®Google Scholar
• Michael E, Malecela-Lazaro MN, Kazura JW. Epidemiological modelling for monitoring and evaluation of lymphatic filariasis control. Adv. Parasitol.65, 191–237 (2007).
   PubMed Web of Science ®Google Scholar
• Stolk WA, de Vlas SJ, Habbema JD. Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J.5, 5 (2006).
   PubMedGoogle Scholar
• Paisier AP, Stolk WA, van Oortmarssen GJ, Habbema JD. Effectiveness of annual ivermectin treatment for Wuchereria bancrofti infection. Parasitol. Today16, 298–302 (2000).
   PubMedGoogle Scholar
• Cao W, van der Ploeg CP, Ren Z, Habbema JD. Success against lymphatic filariasis. World Health Forum18, 17–20 (1997).
   PubMedGoogle Scholar
• Lammie P, Milner T, Housten R. Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis. Bull. World Health Organ.85, 545–549 (2007).
   PubMed Web of Science ®Google Scholar
• El-Setouhy M, Abdel Elaziz KM, Helmy H et al. The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am. J. Trop. Med. Hyg.77, 1069–1073 (2007).
   PubMed Web of Science ®Google Scholar
• Martin RJ. Modes of action of anthelmintic drugs. Vet. J.154, 11–34 (1997).
   PubMed Web of Science ®Google Scholar
• Hoti SL, Subramayinan K, Das PK. Detection of codon for amino acid 200 in isotype 1 β-tubulin gene of Wuchereria bancrofti isolates, implicated in resistance to benzimidazoles in other nematodes. Acta Trop.88, 77–81 (2003).
   PubMed Web of Science ®Google Scholar
• Schwab AE, Churcher TS, Schwab AJ, Basánez MG, Prichard RK. Population genetics of concurrent selection with albendzole and ivermectin or diethylcarbamazine on the possible spread of albendazole resistance in Wuchereria bancrofti. Parasitology133, 589–601 (2006).
   PubMed Web of Science ®Google Scholar
• Sunish IP, Rajendran R, Mani TR, Munirathinam A, Dash AP, Tyagi BK. Vector control complements mass drug administration against bancroftian filariasis in Tirukoilur, India. Bull. World Health Organ.85, 138–145 (2007).
   PubMed Web of Science ®Google Scholar
• Little MP, Basenez MG, Breitling LP, Boatin BA, Alley ES. Incidence of blindness during the onchocerciasis control programme in western Africa, 1971–2002. J. Infect. Dis.189, 1932–1941 (2004).
   PubMed Web of Science ®Google Scholar
• Little MP, Breitling LP, Basañez MG, Alley ES, Boatin BA. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet363, 1514–1521 (2004).
   PubMed Web of Science ®Google Scholar
• Guderian RH, Anselmi M, Espinel M et al. Successful control of onchocerciasis with community-based ivermectin distribution in the Rio Santiago focus in Ecuador. Trop. Med. Int. Health.2, 982–988 (1997).
   PubMed Web of Science ®Google Scholar
• Boatin B, Molyneux DH, Hougard JM et al. Patterns of epidemiology and control of onchocerciasis in West Africa. J. Helminthol.71, 91–101 (1997).
   PubMed Web of Science ®Google Scholar
• Boussinesq M, Chippaux JP, Ernould JC, Quillevere D, Prod’hon J. Effect of repeated treatments with ivermectin on the incidence of onchocerciasis in northern Cameroon. Am. J. Trop. Med. Hyg.53, 63–67 (1995).
   PubMed Web of Science ®Google Scholar
• Chavasse DC, Davies JB. The effect of ivermectin on the uptake and development of O. volvulus microfilariae in S. damnosum s.l. Acta Leiden.59, 227–230 (1990).
   PubMedGoogle Scholar
• Cupp EW, Ochoa JO, Collins RC et al. The effects of repetitive community-wide ivermectin treatment on transmission of Onchocerca volvulus in Guatemala. Am. J. Trop. Med. Hyg.47, 170–180 (1992).
   PubMed Web of Science ®Google Scholar
• Vieira JC, Cooper PJ, Lovato R et al. Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection. BMC Med.5, 9 (2007).
   PubMedGoogle Scholar
• Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann. Trop. Med. Parasitol.102, 13–17 (2008).
   PubMed Web of Science ®Google Scholar
• Sauerbrey M. The Onchocerciasis Elimination Program for the Americas (OEPA). Ann. Trop. Med. Parasitol.102, 25–29 (2008).
   PubMed Web of Science ®Google Scholar
• Sékétéli A, Adeoye G, Eyamba A et al. The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann. Trop. Med. Parasitol.96, S15–S28 (2002).
   Web of Science ®Google Scholar
• Greene BM, Taylor HR, Cupp EW et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N. Engl. J. Med.313, 133–138 (1985).
   PubMed Web of Science ®Google Scholar
• Schulz-Key H, Karam M. Periodic reproduction of Onchocerca volvulus. Parasitol. Today2, 284–286 (1986).
   PubMedGoogle Scholar
• Winnen M, Plaisier AP, Alley ES et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull. World Health Organ.80, 384–391 (2002).
   PubMed Web of Science ®Google Scholar
• Borsboom GJ, Boatin BA, Nagelkerke NJ et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J.2, 8–33 (2003).
   PubMedGoogle Scholar
• Ali MM, Mukhtar MM, Baraka OZ, Homeida MM, Kheir MM, Mackenzie CD. Immunocompetence may be important in the effectiveness of mectizan (ivermectin) in the treatment of human onchocerciasis. Acta Trop.84, 49–53 (2002).
   PubMed Web of Science ®Google Scholar
• Kamgno J, Gardon J, Gardon-Wendel N, Demanga-Ngangue, Duke BO, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans. R. Soc. Trop. Med. Hyg.98, 496–504 (2004).
   PubMed Web of Science ®Google Scholar
• Awadzi K, Boakye DA, Edwards G et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann. Trop. Med. Parasitol.98, 231–249 (2004).
   PubMed Web of Science ®Google Scholar
• Awadzi K, Attah SK, Addy ET et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann. Trop. Med. Parasitol.98, 359–370 (2004).
   PubMed Web of Science ®Google Scholar
• Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet369, 2021–2029 (2007).
   PubMed Web of Science ®Google Scholar
• Ardelli BF, Guerriero SB, Prichard RK. Ivermectin imposes selection pressure on P-glycoprotein from Onchocerca volvulus: linkage disequilibrium and genotype diversity. Parasitology132, 375–386 (2006).
   PubMed Web of Science ®Google Scholar
• Eng JK, Blackhall WJ, Osei-Atweneboana MY et al. Ivermectin selection on β-tubulin: evidence in Onchocerca volvulus and Haemonchus contortus. Mol. Biochem. Parasitol.150, 229–235 (2006).
   PubMed Web of Science ®Google Scholar
• Bourginat C, Pion SD, Kamgno J et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl. Trop. Dis.1, E72 (2007).
   Google Scholar
• Ardelli BF, Prichard RK. Reduced genetic variation of an Onchocerca volvulus ABC transporter gene following treatment with ivermectin. Trans. R. Soc. Trop. Med. Hyg.101, 1223–1232 (2007).
   PubMed Web of Science ®Google Scholar
• Lustigman S, McCarter JP. Ivermectin resistance in Onchocerca volvulus: toward a genetic basis. PLoS Negl. Trop. Dis.1, E76 (2007).
   Google Scholar
• Bourguinat C, Ardelli BF, Pion SD et al. P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Mol. Biochem. Parasitol.158, 101–111 (2008).
   PubMed Web of Science ®Google Scholar
• Grant W. What is the real target for ivermectin resistance selection in Onchocerca volvulus? Parasitol. Today16, 458–459 (2000).
   PubMedGoogle Scholar
• Li BW, Rush AC, Tan J, Weil GJ. Quantitative analysis of gender-regulated transcripts in the filarial nematode Brugia malayi by real-time RT-PCR. Mol. Biochem. Parasitol.137, 329–337 (2004).
   PubMed Web of Science ®Google Scholar
• Huang YJ, Prichard RK. Identification and stage-specific expression of two putative P-glycoprotein coding genes in Onchocerca volvulus. Mol. Biochem. Parasitol.102, 273–281 (1999).
   PubMed Web of Science ®Google Scholar
• Hoerauf A. New strategies to combat filariasis. Expert. Rev. Anti Infect. Ther.4, 211–222 (2006).
   PubMedGoogle Scholar
• Hoerauf A, Mand S, Fischer K et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med. Microbiol. Immunol.192, 211–216 (2003).
   PubMed Web of Science ®Google Scholar
• Hoerauf A, Mand S, Adjei O, Fleischer B, Buttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet357, 1415–1416 (2001).
   PubMed Web of Science ®Google Scholar
• Debrah AY, Mand S, Marfo-Debrekyei Y, Larbi J, Ajei O, Hoerauf A. Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin. Filaria J.5, 1 (2006).
   PubMedGoogle Scholar
• Hoerauf A, Specht S, Büttner M et al.Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med. Microbiol. Immunol.197, 295–311 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomized placebo-controlled trial. Lancet365, 2116–2121 (2005).
   PubMed Web of Science ®Google Scholar
• Debrah AY, Mand S, Specht S et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog.2, E92 (2006).
   Web of Science ®Google Scholar
• Debrah AY, Mand S, Marfo-Debrekyei Y et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop. Med. Int. Health12, 1433–1441 (2007).
   PubMed Web of Science ®Google Scholar
• Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of reinfection in the pathogenesis of trachoma. Rev. Infect. Dis.7, 717–725 (1985).
   PubMedGoogle Scholar
• Mabey DC, Solomon AW, Foster A. Trachoma. Lancet362, 223–229 (2003).
   PubMed Web of Science ®Google Scholar
• Polack S, Brooker S, Kuper H, Mariotti S, Mabey D, Foster A. Mapping the global distribution of trachoma. Bull. World Health Organ.83, 913–919 (2005).
   PubMed Web of Science ®Google Scholar
• Reskinoff S, Pascolini D, Etyua’ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ.82, 844–851 (2004).
   PubMed Web of Science ®Google Scholar
• Schachter J, West SK, Mabey D et al. Azithromycin in control of trachoma. Lancet354, 630–635 (1999).
   PubMed Web of Science ®Google Scholar
• Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin. Infect. Dis.24, 363–368 (1997).
   PubMed Web of Science ®Google Scholar
• Chidambaram JD, Alemayehu W, Melese M et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA295, 1142–1146 (2006).
   PubMed Web of Science ®Google Scholar
• Melese M, Chidambaram JD, Alemayehu W et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA292, 721–725 (2004).
   PubMed Web of Science ®Google Scholar
• Gaynor BD, Miao Y, Cevallos V et al. Eliminating trachoma in areas with limited disease. Emerg. Infect. Dis.9, 596–598 (2003).
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Mkacha H, Gaydos C, Quinn T. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest. Ophthalmol. Vis. Sci.48, 1492–1497 (2007).
   PubMed Web of Science ®Google Scholar
• Chiadambaram JD, Lee DC, Porco TC, Leitman TM. Mass antibiotics for trachoma and the Allee effect. Lancet Infect. Dis.5, 194–196 (2005).
   PubMed Web of Science ®Google Scholar
• Bailey RL, Arullendran P, Whittle HC, Mbey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet342, 453–456 (1993).
   PubMed Web of Science ®Google Scholar
• Kuper H, Solomon AW, Buchan J, Zondervan M, Foster A, Mabey DC. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect. Dis.3, 372–381 (2003).
   PubMed Web of Science ®Google Scholar
• Yorston D, Mabery D, Hatt S, Burton M. Interventions for trachoma trichiasis. Cochrane Database Syst. Rev.3, CD004008 (2006).
   Google Scholar
• Mabey D, Fraser-Hurt N, Powell C. Antibiotics for trachoma. Cochrane Database Syst. Rev.2, CD001860 (2005).
   Google Scholar
• Rabiu M, Alahassan M, Ejere H. Environmental sanitary interventions for preventing active trachoma. Cochrane Database Syst. Rev.4, CD004003 (2007).
   Google Scholar
• Ejere H, Alahassan MB, Rabiu M. Face washing promotion for preventing active trachoma. Cochrane Database Syst. Rev.3, CD003659 (2004).
   Google Scholar
• Solomon A, Burton M. What’s new in azithromycin? Community Eye Health17, 54–56 (2004).
   PubMedGoogle Scholar
• Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull. World Health Organ.65, 477–483 (1987).
   PubMed Web of Science ®Google Scholar
• Kupper H, Solomon AW, Buchan JC, Zondervan M, Mebey CD, Foster A. Participatory evaluations of trachoma control programmes in eight countries. Trop. Med. Int. Health10, 764–772 (2005).
   PubMed Web of Science ®Google Scholar
• Burton MJ, Holland MJ, Makalo P et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet365, 1321–1328 (2005).
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Mlocha H et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet366, 1296–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Ray KJ, Porco TC, Hong KC et al. A rationale for continuing mass antibiotic distributions for trachoma. BMC Infect. Dis.7, 91 (2007).
   PubMedGoogle Scholar
• Gower EW, Solomon AW, Burton MJ et al. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment. Invest. Ophthalmol. Vis. Sci.47, 4767–4671 (2006).
   PubMed Web of Science ®Google Scholar
• Lee S, Alemayenu W, Melese M et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. Am. J. Trop. Med. Hyg.76, 129–131 (2007).
   PubMed Web of Science ®Google Scholar
• Chidambaram JD, Melese M, Alemayehu W et al. Mass antibiotic treatment and community protection in trachoma control programs. Clin. Infect. Dis.39, E95–E97 (2004).
   Google Scholar
• Atik B, Thanh TT, Lunong VQ, Lagree S, Dean D. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA296, 1488–1497 (2006).
   PubMed Web of Science ®Google Scholar
• Jha H, Chaudary JS, Bhatta R et al. Disappearance of trachoma from Western Nepal. Clin. Infect. Dis.35, 765–768 (2002).
   PubMed Web of Science ®Google Scholar
• Dolin PJ, Faal H, Johnson GJ et al. Reduction of trachoma in a sub-Saharan village in absence of a disease control programme. Lancet349, 1511–1512 (1997).
   PubMed Web of Science ®Google Scholar
• Hoechsmann A, Metcalfe N, Kanjaloti S et al. Reduction of trachoma in the absence of antibiotic treatment: evidence from a population-based survey in Malawi. Ophthalmic Epidemiol.8, 145–153 (2001).
   PubMedGoogle Scholar
• Edwards T, Harding-Esch EM, Hailu G et al. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin. Trop. Med. Int. Health13, 556–565 (2008).
   PubMed Web of Science ®Google Scholar
• Ngondi J, Gebre T, Shargie EB et al. Risk factors for active trachoma in children and trichiasis in adults: a household survey in Amhara Regional State, Ethiopia. Trans. R. Soc. Trop. Med. Hyg.102, 432–438 (2008).
   PubMed Web of Science ®Google Scholar
• Melese M, Alemayehu W, Lakew T et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA299, 778–784 (2008).
   PubMed Web of Science ®Google Scholar
• Solomon AW, Mohammed Z, Massae PA et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob. Agents Chemother.49, 4804–4806 (2005).
   PubMed Web of Science ®Google Scholar
• Riska PF, Kutlin A, Ajiboye P, Cua A, Roblin PM, Hammerschlag MR. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. Antimicrob. Agents Chemother.48, 3586–3590 (2004).
   PubMed Web of Science ®Google Scholar
• Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis.181, 1421–1427 (2000).
   PubMed Web of Science ®Google Scholar
• Misyurina OY, Chipitsyna EV, Finashutina YP et al. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob. Agents Chemother.48, 1347–1349 (2004).
   PubMed Web of Science ®Google Scholar
• Smits HL, Leatherman S, Berwick DM. Quality improvement in the developing world. Int. J. Qual. Health Care14, 439–440 (2002).
   PubMed Web of Science ®Google Scholar
• Brooker S, Clements AC, Bundy DA. Global epidemiology, ecology and control of soil-transmitted helminth infections. Adv. Parasitol.62, 221–261 (2006).
   PubMed Web of Science ®Google Scholar
• Brooker S, Utzinger J. Integrated disease mapping in a polyparasitic world. Geospat. Health1, 141–146 (2007).
   PubMed Web of Science ®Google Scholar
• Simeonov A, Jadhav A, Sayed AA et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl. Trop. Dis.2, E127 (2008).
   Google Scholar
• Diemert DJ, Bethony JM, Hotez PJ. Hookworm vaccines. Clin. Infect. Dis.46, 282–288 (2008).
   PubMed Web of Science ®Google Scholar
• McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin. Microbiol. Rev.21, 225–242 (2008).
   PubMed Web of Science ®Google Scholar
• Choi EH, Nutman TB, Chanocl SJ. Genetic variation in immune function and susceptibility to human filariasis. Expert Rev. Mol. Diagn.3, 367–374 (2003).
   PubMed Web of Science ®Google Scholar
• Nutman TB. Future directions for vaccine-related onchocerciasis research. Trends Parasitol.18, 237–239 (2002).
   PubMed Web of Science ®Google Scholar
• Lusstigman S, James ER, Tawe W, Abraham D. Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol.18, 135–141 (2002).
   PubMed Web of Science ®Google Scholar
• Dean D, Kandel RP, Adhikari HK, Hessel T. Multiple Chlamydiaceae species in trachoma: implications for disease pathogenesis and control. PLoS Med.5, E14 (2008).
   Web of Science ®Google Scholar
• Ruiz JH, Becker I. CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol.29, 671–678 (2007).
   PubMed Web of Science ®Google Scholar
• Mansueto P, Vitale G, Di Lorenzo G, Rini GB, Mansueto S, Cillari E. Immunopathology of leishmaniasis: an update. Int. J. Immunopathol. Pharmacol.20, 435–445 (2007).
   PubMed Web of Science ®Google Scholar
• Brooker S, Akhwale W, Pullan R et al. Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control. Am. J. Trop. Med. Hyg.77, 88–98 (2007).
   PubMed Web of Science ®Google Scholar
• Blackburn BG, Eigege A, Gotau H et al. Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria. Am. J. Trop. Med. Hyg.75, 650–655 (2006).
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Fischer TK, Deming M et al. Point-of-use water treatment and use among mothers in Malawi. Emerg. Infect. Dis.13, 1077–1080 (2007).
   PubMed Web of Science ®Google Scholar
• Segarra-Newham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann. Pharmacother.41, 1992–2001 (2007).
   PubMed Web of Science ®Google Scholar
• Toma H, Shimabukuro I, Koyabashi J, Tasaki T, Takata M, Sato Y. Community control studies on Strongyloides infection in a model island of Okinawa, Japan. Southeast Asian J. Trop. Med. Public Health31, 383–387 (2000).
   PubMedGoogle Scholar
• Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol.5, 873–882 (2007).
   PubMed Web of Science ®Google Scholar
• Sunda S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med.347, 1739–1746 (2002).
   PubMed Web of Science ®Google Scholar
• Singer BH, de Castro MC. Bridges to sustainable tropical health. Proc. Natl Acad. Sci. USA104, 16038–16043 (2007).
   PubMed Web of Science ®Google Scholar